These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 829620)

  • 1. [Depot fluphenazine as a means of stabilizing remission in cases of schizophrenia].
    Vovin RIa; Vovina EN
    Psychiatr Neurol Med Psychol Beih; 1975; 20-21():183-7. PubMed ID: 829620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine.
    Schooler NR; Levine J
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jul; 9(4):159-69. PubMed ID: 790413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Results of therapy with Lyogen-Depot in schizophrenic diseases].
    Friemert K; Beier R; Vehreschild T
    Psychiatr Neurol Med Psychol (Leipz); 1974 Jun; 26(6):374-7. PubMed ID: 4849639
    [No Abstract]   [Full Text] [Related]  

  • 4. [Experience with the depot neuroleptic LyogenR-depot].
    Bach O; Petermann H; Geppert V
    Psychiatr Neurol Med Psychol (Leipz); 1978 Sep; 30(9):563-6. PubMed ID: 733993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosage and side effect comparisons betweel oral and depot fluphenazine.
    Schooler NR; Levine J
    Psychopharmacol Bull; 1977 Jul; 13(3):29-31. PubMed ID: 329328
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of moditen-depot therapy on the duration and quality of remissions in schizophrenia patients].
    Vovin RIa; Gurovich IIa; Eryshev OF; Zaĭtsev SG; Magalif AIu
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1977; 77(5):743-9. PubMed ID: 899478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
    Cohen BM; Waternaux C; Chouinard G; Sommer BR; Jones B
    J Clin Psychopharmacol; 1985 Dec; 5(6):328-32. PubMed ID: 4066997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depot fluphenazine in the prevention of relapse in schizophrenia: evaluation of a treatment regimen [proceedings].
    Schooler NR; Levine J; Severe JB
    Psychopharmacol Bull; 1979 Apr; 15(2):44-7. PubMed ID: 373006
    [No Abstract]   [Full Text] [Related]  

  • 10. Our experience with Moditene-Depot in chronic schizophrenia.
    Gamkrelidze ShA; Putkoradze-Gamkrelidze NA
    Act Nerv Super (Praha); 1973 Aug; 15(3):169. PubMed ID: 4769133
    [No Abstract]   [Full Text] [Related]  

  • 11. [Characteristics of the therapeutic action fluphenzaine decanoate (moditen-depot) in schizophrenia].
    Tsutsul'kovskaia MIa; Minsker EI; Panteleeva GP; Mazurskii MB; Pekunova LG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(5):753-8. PubMed ID: 4718619
    [No Abstract]   [Full Text] [Related]  

  • 12. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
    Wiles DH; Gelder MG
    Adv Biochem Psychopharmacol; 1980; 24():599-602. PubMed ID: 7405678
    [No Abstract]   [Full Text] [Related]  

  • 13. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia.
    Leong OK; Wong KE; Tay WK; Gill RC
    Singapore Med J; 1989 Oct; 30(5):436-40. PubMed ID: 2575796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Characteristics of the psychotropic activity of long-acting drugs (experience in the use of Moditen-depot)].
    Smulevich AB; Minsker EI; Mazaeva NA; Volkova RP; Lukanina SK
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1972; 72(6):912-20. PubMed ID: 5050051
    [No Abstract]   [Full Text] [Related]  

  • 15. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study.
    Levine J; Schooler NR; Severe J; Escobar J; Gelenberg A; Mandel M; Sovner R; Steinbook R
    Adv Biochem Psychopharmacol; 1980; 24():483-93. PubMed ID: 6996445
    [No Abstract]   [Full Text] [Related]  

  • 16. Early hospital experience with fluphenazine decanoate.
    Small JG; Kellams J
    Dis Nerv Syst; 1974 Oct; 35(10):453-6. PubMed ID: 17894058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Results of the use of fluphenazine in a depot preparation].
    Marcjan K; Pietruszewska I; Wolak E
    Psychiatr Neurol Med Psychol Beih; 1975; 20-21():176-82. PubMed ID: 829619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
    Dencker SJ
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine.
    Marder SR; Van Putten T; Aravagiri M; Hubbard JW; Hawes EM; McKay G; Midha KK
    Psychopharmacol Bull; 1989; 25(3):479-82. PubMed ID: 2626520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance treatment of schizophrenia with long-acting fluphenazine.
    Niturad A; Ciurezu T; Cucu I
    Act Nerv Super (Praha); 1974 Aug; 16(3):167. PubMed ID: 4154028
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.